Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis

E. Laukhtina, K. Mori, H. Mostafaei, AS. Merseburger, P. Nyirady, M. Moschini, F. Quhal, VM. Schuettfort, B. Pradere, RS. Motlagh, D. Enikeev, SF. Shariat, EA. Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group

. 2021 ; 13 (11) : 917-929. [pub] 20210603

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012316
E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2009-01-01 do 2021-04-30
Health & Medicine (ProQuest) od 2009-01-01 do 2021-04-30
Public Health Database (ProQuest) od 2009-01-01 do 2021-04-30

Odkazy

PubMed 34078134
DOI 10.2217/imt-2020-0305
Knihovny.cz E-zdroje

Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012316
003      
CZ-PrNML
005      
20220506130845.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/imt-2020-0305 $2 doi
035    __
$a (PubMed)34078134
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $1 https://orcid.org/0000000289530272
245    10
$a Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis / $c E. Laukhtina, K. Mori, H. Mostafaei, AS. Merseburger, P. Nyirady, M. Moschini, F. Quhal, VM. Schuettfort, B. Pradere, RS. Motlagh, D. Enikeev, SF. Shariat, EA. Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
520    9_
$a Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a karcinom z přechodných buněk $x farmakoterapie $7 D002295
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x škodlivé účinky $x metody $7 D007167
650    _2
$a síťová metaanalýza $7 D000071076
650    _2
$a záchranná terapie $x metody $7 D016879
650    _2
$a nádory močového měchýře $x farmakoterapie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
700    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz , 5166, Iran $1 https://orcid.org/0000000155961771
700    1_
$a Merseburger, Axel S $u Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck , 23562, Germany $1 https://orcid.org/0000000164673931
700    1_
$a Nyirady, Peter $u Department of Urology, Semmelweis University, Budapest, 1082, Hungary $1 https://orcid.org/0000000270374919
700    1_
$a Moschini, Marco $u Department of Urology, Luzerner Kantonsspital, Lucerne , 6000, Switzerland $u Department of Urology & Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan , 20132, Italy $1 https://orcid.org/0000000230842458
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam , 32253, Saudi Arabia $1 https://orcid.org/0000000281636953
700    1_
$a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany $1 https://orcid.org/0000000271140508
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $1 https://orcid.org/0000000277688558
700    1_
$a Motlagh, Reza Sari $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $1 https://orcid.org/0000000238199911
700    1_
$a Enikeev, Dmitry $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $1 https://orcid.org/0000000171692209
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $u Department of Urology, Weill Cornell Medical College, New York, NY 14853, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague , 15006, Czech Republic $u Karl Landsteiner Institute of Urology & Andrology, Vienna , 1010, Austria $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman , 11942, Jordan $1 https://orcid.org/0000000266276179
700    1_
$a Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group, European Association
773    0_
$w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 13, č. 11 (2021), s. 917-929
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34078134 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130838 $b ABA008
999    __
$a ok $b bmc $g 1789764 $s 1163517
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 11 $d 917-929 $e 20210603 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace